Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397692 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2AMEN1CACNA1GCACNA1H | |
| SCHEMBL12021175 | 0.88 | BRD4 (0.43) | SMN1; SMN2KMT2AMEN1CACNA1GCACNA1H | |
| SCHEMBL14504287 | 0.75 | CACNA1G (0.44) | SMN1; SMN2KMT2AMEN1CACNA1GCACNA1H | |
| SCHEMBL14620323 | 0.73 | CACNA1G (0.43) | KMT2AMEN1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL400299 | 0.73 | CACNA1I (0.49) | KMT2AMEN1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL14629510 | 0.72 | CACNA1G (0.42) | CACNA1GCACNA1HCACNA1ICYP3A4 | |
| SCHEMBL750547 | 0.72 | CLPP (0.45) | CYP3A4 | |
| SCHEMBL16623163 | 0.72 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL14620166 | 0.71 | CLPP (0.59) | — | |
| SCHEMBL13673303 | 0.71 | KMT2A (0.52) | SMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8318738-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8106049-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106049-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-01 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-7531320-B2 | Modulation of β-catenin/TCF-activated transcription | CHOONGWAE PHARMA CORPORATION (KR) | 2009-05-12 | — | — | US | disclosed |
| US-7531320-B2 | Modulation of β-catenin/TCF-activated transcription | CHOONGWAE PHARMA CORPORATION (KR) | 2009-05-12 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | SMN1; SMN2 4611/4885KMT2A 4111/4885MEN1 336/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | SMN1; SMN2 4611/4885KMT2A 4111/4885MEN1 336/4885 |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | SMN1; SMN2 4611/4885KMT2A 4111/4885MEN1 336/4885 |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | SMN1; SMN2 4611/4885KMT2A 4111/4885MEN1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.